MYGN Q1 2023 Earnings — Myriad Genetics, Inc. Revenue & Financial Results | Market Cap Arena

MYGNMyriad Genetics, Inc.

$487M

Q1 2023 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$181M+9.9% YoY

Gross Profit

$122M67.3% margin

Operating Income

-$52M-28.8% margin

Net Income

-$55M-30.2% margin

EPS (Diluted)

$-0.67

QoQ Revenue Growth

+1.9%

Cash Flow

Operating Cash Flow

-$33M

Free Cash Flow

-$57M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$334M

Stockholders' Equity

$835M

Cash & Equivalents

$54M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$181M	$165M	+9.9%
Gross Profit	$122M	$117M	+4.4%
Operating Income	-$52M	-$15M	-250.3%
Net Income	-$55M	-$21M	-166.8%

Geographic Segments

UNITED STATES

$29M77%

Non-US

$9M23%